Vytrus Biotech says European skin rejuvenation patent validated in seven countries

Reuters2026/09/07 16:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Vytrus Biotech secured national validation in seven European markets for its EP 3283092 skin rejuvenation or wound-healing patent.
Patent granted on April 29, 2026; protection runs until April 11, 2036.
Europe represented 70% of 2025 sales, reinforcing the strategic value of expanded patent coverage in the region.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vytrus Biotech SA published the original content used to generate this news brief on September 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Vytrus Biotech says European skin rejuvenation patent validated in seven countries

You may also like

Crypto prices